UCL shortened volunteers' pain by sparing the fat molecules that end inflammation

Each treated-versus-placebo comparison in this trial comes down to 12 volunteers against 12 ^[5][6]. There are two of them, one dosed two hours before the forearm injection and one dosed four hours after ^[5][6], so 48 people took part and 24 of them received GSK2256294 ^[1][2]. The arms differ in dosing time, and both produced similar results ^[7].

The design is what makes the human data readable. UV-killed E. coli cannot establish an infection, but injected into the forearm it still produces pain, redness, heat and swelling ^[3]. That yields an episode of inflammation with a known start time. How inflammation begins has been well described for years; the open question the UCL group went after is how the body decides the danger has passed and turns to repair ^[17].

The target is a disposal enzyme. Soluble epoxide hydrolase normally breaks epoxy-oxylipins down, and GSK2256294 blocks it, so more of those molecules stay in the body ^[4]. Blocking the enzyme raised epoxy-oxylipin levels, sped pain resolution and sharply reduced intermediate monocytes in blood and tissue ^[8].

Pain was the only one of the four cardinal signs reported to improve ^[3]. At 12 treated against 12 on placebo, a modest change in swelling would not have reached significance in either direction ^[4]. UCL's interpretation is that the drug was altering deeper immune processes while the visible symptoms stayed much the same ^[10].

For the molecular account, one epoxy-oxylipin, 12,13-EpOME, suppresses p38 MAPK, the signalling pathway that pushes monocytes into the intermediate form associated with prolonged inflammatory activity ^[11]. The team checked this in laboratory experiments and in volunteers who received a drug that blocks p38 directly ^[12]. That second check is the useful one, because interrupting the pathway downstream tests the assignment itself.

"Our findings reveal a natural pathway that limits harmful immune cell expansion and helps calm inflammation more quickly," said Olivia Bracken, the study's first author, of UCL's Department of Ageing, Rheumatology and Regenerative Medicine ^[13][14].

Lowering the intermediate monocyte count is a plausible stand-in for clinical benefit, since those cells have been linked to persistent inflammation and to the progression of inflammatory disease ^[15]. That link is an association carried in from earlier work. The release, published on September 12, reports which way each result went and gives no figures for the monocyte reduction or the pain difference ^[18][19].